Drug intelligence / Profile preview

choline + ranitidine

Development stage: Unknown
Lead developer: Physician Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

A combination product containing ranitidine hydrochloride (150 mg) and choline. Ranitidine is a histamine H2-receptor antagonist that decreases gastric acid secretion, while choline is included as a dietary supplement component. The product was marketed as a medical food kit for the dietary management of sleep disorders, combining the ranitidine tablet with Sentra PM capsules. This was an unapproved drug product that was marketed by Physician Therapeutics LLC. Ranitidine products were withdrawn from the market in 2020 due to concerns about NDMA (N-nitrosodimethylamine) contamination, a probable carcinogen.

Brand names: SentradineGabitidine
Other names: ranitidine hydrochloride + choline bitartrate

Targets

HRH2 (Histamine H2 Receptor)

Beyond the preview

Go deeper on choline + ranitidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on choline + ranitidine.

Explore the full profile